Group
Multi-target TKI
The data below refer to patients treated with Multi-target TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Combination therapy data are available in the section below.
Location
Treated site
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Axitinib
Cabozantinib
Crizotinib
Lapatinib
Lenvatinib
Pazopanib
Sorafenib
Sunitinib
Avapritinib
No data
Entrectinib
No data
Nilotinib
No data
Nintedanib
No data
Regorafenib
No data
Repotrectinib
No data
Ripretinib
No data
Vandetanib
No data